SCHEMBL10094186

SCHEMBL10094186

Nc1nc(Cl)c(-c2ccccc2)c(N[C@H]2CC[C@@H](CO)C2)n1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 1/20 0.43
▸ ACHE P22303 2/20 0.37
▸ PTPN11 Q06124 1/20 0.36
▸ BTK Q06187 5/20 0.35
▸ GHSR Q92847 1/20 0.35
▸ NR1I2 O75469 1/20 0.34
▸ ALB P02768 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ SYK P43405 4/20 0.34
▸ ACP1 P24666 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ MDM2 Q00987 1/20 0.34
▸ PIM1 P11309 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12057657 0.91 BTK (0.46) IRAK4BTKSYK
SCHEMBL10094255 0.87 IRAK4 (0.41) IRAK4PTPN11BTKNR1I2ALB
SCHEMBL10094252 0.86 IRAK4 (0.43) IRAK4NR1I2ALBPDE4DSYK
SCHEMBL10094152 0.85 TYRO3 (0.37) IRAK4PTPN11GHSRNR1I2ALB
SCHEMBL10094144 0.83 IRAK4 (0.37) IRAK4PTPN11BTKGHSRNR1I2
SCHEMBL12058044 0.83 IRAK4 (0.37) IRAK4BTKSYKPIM1
SCHEMBL10094250 0.83 IRAK4 (0.38) IRAK4PTPN11BTKNR1I2ALB
SCHEMBL13493538 0.81 IRAK4 (0.67) IRAK4
SCHEMBL12058383 0.81 IRAK4 (0.46) IRAK4NR1I2ALBPDE4D
SCHEMBL10094048 0.81 ACHE (0.36) IRAK4ACHEBTKNR1I2ALB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120107271-A1 ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS MERCK SHARP & DOHME LLC 2012-05-03 — — US disclosed
US-20110318305-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS MERCK SHARP & DOHME LLC 2011-12-29 — — US disclosed
WO-2010022121-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2010-02-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120107271-A1 ETHYNYL-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS CYP2C9, P2RX3, F12 IRAK4 951/4885ACHE 1716/4885PTPN11 819/4885
US-20110318305-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS PNP, XDH, PNPO IRAK4 706/4885ACHE 1592/4885PTPN11 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback